We have already demonstrated that the serine/threonine kinase PLK1 is hyper-activated in the progenitor cell compartment of CML consisting of CD34+/BCR::ABL1+ cells, and that together with Aurora kinase A up-modulation, it contributes to TKI resistance (15). This evidence concerns the gene MARK2 and chronic myelogenous leukemia, BCR-ABL1 positive.